Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Working Capital Changes: 2014-2025

Historic Other Working Capital Changes for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $2.8 million.

  • Zevra Therapeutics' Other Working Capital Changes rose 249.60% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 469.72%. This contributed to the annual value of $2.2 million for FY2024, which is N/A change from last year.
  • Zevra Therapeutics' Other Working Capital Changes amounted to $2.8 million in Q3 2025, which was up 97.90% from $1.4 million recorded in Q2 2025.
  • Zevra Therapeutics' Other Working Capital Changes' 5-year high stood at $3.3 million during Q4 2024, with a 5-year trough of -$1.9 million in Q3 2024.
  • Over the past 3 years, Zevra Therapeutics' median Other Working Capital Changes value was $560,000 (recorded in 2025), while the average stood at $601,091.
  • Over the last 5 years, Zevra Therapeutics' Other Working Capital Changes had its largest YoY gain of 4,356.92% in 2021, and its largest YoY loss of 6,535.29% in 2021.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Other Working Capital Changes stood at -$541,000 in 2021, then soared by 44.18% to -$302,000 in 2022, then tumbled by 282.45% to -$1.2 million in 2023, then soared by 382.16% to $3.3 million in 2024, then surged by 249.60% to $2.8 million in 2025.
  • Its Other Working Capital Changes stands at $2.8 million for Q3 2025, versus $1.4 million for Q2 2025 and $560,000 for Q1 2025.